Journal Publishes GrafixA Clinical Study for Chronic Wounds

Osiris Therapeutics, Inc. , the leading stem cell company focused on developing and marketing products in orthopedics, sports medicine and wound care, announced today that data, published in Ostomy Wound Management , shows that the use of GrafixA on a variety of chronic wounds resulted in an overall closure rate of 76% by 12 weeks, including 68% of ... (more)

http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20131218005690&newsLang=en&ndmConfigId=1000639&vnsId=41